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Abstract 17 
 18 
In mammals, the large IGF-I gene comprises 6 exons, which are subject to alternative splicing. All 19 
transcripts contain exons 3 and 4, encoding mature IGF-I, but the other exons are included in various 20 
combinations, giving at least 6 possible mature mRNAs. At the 5' end, exons 1 and 2 are spliced 21 
alternatively to exon 3, giving different leader/signal sequences. It is shown in this study that in human 22 
an additional exon (designated exon 0) is present, upstream of exon 1. This can be spliced directly to 23 
exon 3 or, less frequently, into exon 1. Exon 0 is utilised in liver, in about 24% of IGF-I transcripts, to 24 
a minor extent in prostate and endometrium (<1% of transcripts), but not in any of 29 other normal 25 
human tissues examined. The exon 0 sequence includes an in-frame ATG/AUG, potentially providing a 26 
translation start point giving an IGF-I precursor with a very long signal peptide. However, this ATG is 27 
very close to the 5' end, and may not be included in all transcripts; an in-frame ATG in exon 3 could 28 
provide an alternative start point. Utilization of exon 0 was detected in other apes, and to a small extent 29 
in Old World monkeys, but not in New World monkeys, prosimians or various non-primate mammals. 30 
Exon 0 was not expressed in most human tumours, but was utilized in many prostate tumours, at levels 31 
much greater than seen in normal prostate, and in liver tumours, at a lower level than in normal liver. 32 
 33 
Keywords: IGF-I, exon 0, alternative splicing, liver, primates, prostate cancer 34 
 35 
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1. Introduction 37 
 38 
Insulin-like growth factor I (IGF-I) is a small protein formed from a larger precursor, encoded by a 39 
very large gene extending over ~85 kb in human. In mammals this gene comprises at least 6 exons, 40 
with the sequence encoding mature IGF-I included in exons 3 and 4. Alternative splicing allows these 41 
two exons to be combined with various combinations of the others, leading to production of at least 6 42 
different IGF-I precursors [1-3] all of which include the sequence of mature IGF-I, which is generally 43 
strongly conserved [4-6]. At the 5' end the alternative splicing leads to production of mRNAs and IGF-44 
I precursors with differing leader/signal sequences while at the 3' end varying amino acid (aa) 45 
sequences are produced, which can be processed to a number of peptides with potential biological 46 
actions [2-5]. IGF-I is produced in many tissues, and has both endocrine and paracrine actions. It  47 
mediates the actions of pituitary growth hormone, forming the basis of the somatomedin hypothesis 48 
[7,8]. Initially this mediating role was thought to involve circulating IGF-I, but more recent evidence 49 
suggests that paracrine actions may be more important [8]. Nevertheless, most IGF-I in the body is 50 
found in the circulation, associated with IGF binding proteins [1]. The source of this circulating IGF-I 51 
appears to be largely the liver [9,10] though its function is unclear [8]. 52 
 53 
Alternative splicing at the 5' end of the IGF-I gene has been widely studied, especially in rodents and 54 
human, though its significance remains poorly understood. In mammals (but not other vertebrates, 55 
where there is no equivalent of mammalian exon 2 [11]) exon 3 can be spliced to either exon 1 or exon 56 
2, giving mRNA variants that encode IGF-I precursors with signal peptides of respectively 48 or 32 57 
amino acid residues (aas) preceding the mature IGF-I sequence.  Studies using cell-free systems 58 
showed that with rat mRNAs, signal peptides of these lengths are indeed produced [12,13] although 59 
initiation of translation can also occur at an ATG/AUG within exon 3, giving a signal peptide of 22 aas 60 
[13]. Translational efficiency appeared to be much greater for the 32 and 22 aa signal peptide forms 61 
than for the 48 aa variant [13]. Further complications are introduced because transcription of both exon 62 
1 and exon 2 is initiated at multiple sites, giving mRNAs with untranslated regions (utrs) of variable 63 
length [14,15]; for the shortest of these in exon 1, the potential initiating AUG is missing, so translation 64 
would presumably start in exon 3. Yet another complication in rat is the occurrence of a deletion of 186 65 
nt within the 5' utr in some transcripts, apparently due to another splicing event [16]; this deletion 66 
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removes some of the potential transcription initiation sites. The significance of all this variation at the 67 
5' end of the IGF-I mRNA (and potentially the N-terminus of the IGF-I precursor) is unclear. Use of 68 
alternative leader sequences, with different promoter sequences may allow differential regulation of 69 
expression, for example between tissues or developmental stages [17-20] or in response to growth 70 
hormone [21-23]. Initiation of translation at different points can occur with differing efficiency, as 71 
discussed. Use of different signal sequences could result in varying intracellular localization of IGF-I 72 
precursors and/or post-translational modification [24]. The physiological importance of these various 73 
possibilities remains to be determined. 74 
 75 
In light of this, the variation of the alternative splicing observed for IGF-I between different tissues, 76 
developmental stages and species is clearly of interest. In primates, variation in splicing across tissues 77 
has been assessed to some extent in human, but has been little studied in other primate species. The 78 
availability of large amounts of data on gene transcription in the ncbi SRA database makes possible the 79 
assessment of IGF-I splicing in a number of primate species. Such a study is reported here, focussing 80 
particularly on splicing at the 5' end of the gene.  It was found that splicing does vary considerably 81 
among different tissues and species. Most notably, a novel exon, encoding a third 5' leader sequence, 82 
was found to be used in human and some other primates, expressed primarily in liver and some 83 
tumours, and associated with a substantial proportion of IGF-I transcripts. 84 
 85 
2. Methods 86 
 87 
2.1. Sequence and transcriptomic data 88 
The sequences of IGF-I genes for a range of primates and other mammals were obtained using the 89 
Ensembl genome browser (www.ensembl.org). Releases used were as follows: human (Homo sapiens) 90 
GRCH38, chromosome 12; chimpanzee (Pan troglodytes) Pan_tro_3.0, chromosome 12; gorilla 91 
(Gorilla gorilla) gorGor4, chromosome 12; orangutan (Pongo pygmaeus) PPYG2, chromosome 12; 92 
gibbon (Nomascus leucogenys) Nleu_3.0, chromosome 10; rhesus macaque (Macaca mulatta) 93 
Mmul_8.0.1, chromosome 11; African green monkey (vervet, Chlorocebus sabaeus) ChlSabl.1, 94 
chromosome 11; marmoset (Callithrix jacchus) ASM275486v1, contig NTIC01000002.1; squirrel 95 
monkey (Saimiri boliviensis) SaiBol1.0, scaffold JH378139; tarsier (Tarsier syrichta now renamed 96 
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Carlito syrichta) Tarsius_syrichta-2.0.1, scaffold KE941348.1; mouse lemur (Microcebus murinus) 97 
Mmur_3.0, chromosome 7; galago (Otolemur garnettii) OtoGar3, scaffold GL873526.1; tree shrew 98 
(Tupaia belangeri) tupBel1, scaffold GeneScaffold_475; rat (Rattus norvegicus) Rnor_6.0, 99 
chromosome 7; rabbit (Oryctolagus cuniculus) OryCun2.0, chromosome 4; dog (Canis familiaris) 100 
CanFam3.1, chromosome 15. Exons in these genes were identified by comparison with the human and 101 
rat genes; the gene structure for IGF-I is known to be well conserved across mammals [4]. 102 
 103 
Transcriptomes were accessed via the SRA database (trace.ncbi.nlm.nih.gov/Traces/sra). The SRA 104 
projects used in this study are summarized in Supplementary Table 1. 105 
 106 
2.2. Transcriptome analysis 107 
Each transcriptome database (experiment) was subjected to BLAST searches [25] on the SRA website, 108 
using IGF-I sequences from the appropriate species. For each transcriptome, sequences with exon 3  109 
linked at the 5' end to exon 0, exon 1 and exon 2 respectively were used to determine the relative usage 110 
of these three exons. Full sequences of these Blast Queries are given in Supplementary Table 2. 111 
Expression of IGF-I in various tissues was determined by BLAST analysis with the sequence encoding 112 
mature IGF-I (since this is included in all IGF-I precursor transcripts) and expressed as BLAST 113 
hits/million reads. 114 
 115 
2.3. Exon profiling 116 
To obtain a graphical visualization of the relative usage of the exons at the 5' end of the IGF-I gene, an 117 
in-house perl programme was used. The perl script is given in Supplementary Method 1. Input for this 118 
programme was the Blast alignment output produced by searching the corresponding transcriptomic 119 
database with a section of the IGF-I gene extending from about 5000 nt upstream of exon 1 to about 120 
2000 nt downstream of exon 3. The output from the programme gave the number of representations in 121 
the alignment for each nucleotide, which was converted to graphical form using Microsoft Excel. 122 
Identification of repetitive sequence elements was performed using RepeatMasker [26]. 123 
 124 
2.4. Statistical analysis 125 
Statistical analysis was carried out using the R package  (www.R-project.org). 126 
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 127 
 128 
3. Results 129 
 130 
3.1. A novel 5' utr and leader sequence for human IGF-I (exon 0) 131 
Investigation of sequences spliced to the 5' end of IGF-I exon 3 in human liver transcriptomes (initially 132 
in SRA project ERP003613) revealed not only sequences corresponding to exons 1 and 2, but 133 
additional sequence corresponding to a region about 1380 nucleotides (nt) upstream of the 3' end of 134 
exon 1. BLAST analysis of this region identified a new IGF-I leader exon extending over about 145 nt 135 
(Fig.1), though the majority of reads corresponded to a shorter sequence of 110 nt. This novel exon is 136 
referred to as exon 0. In the majority of transcripts (~90%) it is spliced to the 5' end of exon 3, but in a 137 
minority it is spliced into a site 82 nt upstream of the 3' end of exon 1. Exon 0 contains an in-frame 138 
ATG/AUG which would allow production of a very long signal peptide of 65 aas (Fig.1). However, 139 
this ATG is close to the apparent (putative) 5' end of the majority of transcripts, and has weak 140 
surrounding sequence for an initiating AUG [27], so it is doubtful whether initiation starts at this point. 141 
If not, initiation would be expected to start at the first in-frame ATG/AUG in exon 3, giving a signal 142 
peptide of 25 aas; the equivalent signal sequence in rat is known to be functional [13] though a little 143 
shorter (22 aas). 144 
 145 
Exon profiling for the 5' end of the human IGF-I gene, including exons 0-3 and ~4750 nt upstream of 146 
exon 0 confirmed the expression of exon 0 in human liver, as well as exons 1 and 2 (Fig. 2). Minor 147 
peaks between exons 0 and 1, exons 1 and 2 and exons 2 and 3 may reflect traces of unspliced or 148 
undegraded introns; none of these showed evidence for splicing to exons. The small peak ~3800 nt 149 
upstream of exon 0 was identified by RepeatMasker as an L1-like repetitive element, with again no 150 
evidence for splicing to an exon. All the exon 3 sequences in this transcriptome that ran up from the 5' 151 
splice site were spliced to exon 0, exon 1 or exon 2.  On the basis of the profile of Fig. 2, exon 1 is the 152 
major 5' leader sequence, but exon 0 appears to be more highly represented than exon 2. 153 
 154 
Expression of exon 0 was observed in all normal human liver transcriptomes examined (from 11 155 
individuals in 5 separate SRA projects). Exon 1 to exon 3 splices predominated (71% of all such 156 
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splices), with exon 0-exon 3 splices at 22%, exon 2-exon 3 6% and exon 0-exon 1-exon 3 2% (Fig. 3). 157 
However, the range of values was large (Fig.3), probably reflecting the fact that liver samples were 158 
obtained from a wide range of individuals with no controlling for sex, age or physiological state. In 159 
many cases such information was not available. Where replicate values for individuals were available, 160 
agreement was close. 161 
 162 
3.2. Expression of IGF-I and alternative splicing in normal human tissues 163 
Any one of three upstream exons can be used in the expression of the human IGF-I gene, with exon 0, 164 
1 or 2 spliced to the 5' of exon 3 and in addition, a minor variant in which exon 0 is spliced into exon 1 165 
(Fig. 1). Each of these variants gives a different leader sequence on the derived mRNA, and potentially 166 
a different signal peptide on the IGF-I precursor. The patterns of expression of these variants in a wide 167 
variety of human tissues was determined using transcriptomic data from SRA projects ERP003613 and 168 
ERP006650 [28] and is summarized in Fig. 4.  Fig. 4A shows the expression level of IGF-I for each 169 
tissue, determined by a BLAST search using  the coding sequence for mature IGF-I, and expressed as 170 
BLAST hits/106 reads. Expression levels vary markedly between tissues, and for some tissues 171 
(particularly endometrium, liver and smooth muscle) between individuals. Replicates for individuals 172 
generally showed good agreement.  The level seen for liver was similar to the mean for the 11 173 
individuals of Fig. 3 (4.20 ± 0.92 BLAST hits/106 reads). Several tissues show an expression 174 
level similar to that in liver. All 32 tissues studied showed some expression of IGF-I, though 175 
levels in skin, bone marrow, skeletal muscle and pancreas were very low. 176 
 177 
Fig. 4B indicates the relative proportions of splices of exons 0, 1 and 2 to exon 3 for each tissue. Use of 178 
exon 0 was seen in liver and to a very minor extent (less than 1%) in prostate gland and endometrium, 179 
but not in any other tissue. Use of exon 1 was predominant in all tissues. The  percent utilization of 180 
exon 2 varied between tissues, and this variation was shown to be significant by one-way analysis of 181 
variance (p<0.001). High variability was seen for some tissues; this, and the failure to detect any exon 182 
2-exon 3 splices in some tissues may have been due to the low number of exon 2-exon 3 BLAST hits 183 
obtained for tissues with low overall expression of IGF-I. 184 
 185 
3.3. Expression and alternative splicing of IGF-I in non-human primates 186 
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An alignment of exon 0-like sequences derived from genomic sequences of various primates and a few 187 
non-primate mammals is shown in Fig. 5. Strong similarity is seen between primate sequences, but is 188 
less clear cut for non-primates. Rat sequence was not included because a convincing alignment could 189 
not be produced. The positions of two potential initiating ATGs is shown. After splicing to exon 3 the 190 
more upstream of these (ATG-1) is in-frame with the IGF-I coding sequence for the human sequence. 191 
The chimpanzee sequence is identical to that of human. Gorilla, orangutan and gibbon sequences are 192 
very similar to human, but insertion of an additional base (A) in the long A-tract changes the reading 193 
frame so that the downstream ATG (ATG-2) rather than ATG-1 is in-frame. Sequences for two Old-194 
World monkeys (macaque and vervet) differ more from human; insertion of 6 bases leaves ATG-1 in-195 
frame. Sequences of two New-World monkeys (marmoset and squirrel monkey) show a 9 base 196 
deletion, compared with human, in the region of the long A-tract; this would potentially leave the 197 
reading frame unchanged, but mutation of ATG-1 to CTG would prevent translation initiation from this 198 
site. Sequences from prosimians (tarsier, mouse lemur and galago) diverge further from human, and 199 
include a number of insertions/deletions (indels).  Sequences of non-primates are even more divergent, 200 
with convincing alignment difficult to establish at the 5' end. 201 
 202 
Expression of IGF-I was seen in livers of three apes (chimpanzee, gorilla and orangutan; no liver 203 
transcriptomic data is available in the SRA for gibbon) and in the various other primates and non-204 
primates studied (Fig. 6A).  Notably the expression level in human liver was lower than that in any 205 
other species except chimpanzee (though for gorilla, orangutan and squirrel monkey data from only 206 
two individuals were available, so this conclusion must be tentative). The level of IGF-I mRNA in rat 207 
liver was about 25-fold greater than that in human. 208 
 209 
Utilization of exon 0 was seen in liver transcriptomes from the apes for which data is available 210 
(chimpanzee, gorilla and orangutan) though in all cases it was lower than in human. Exon 0 was also 211 
utilized, but to a very minor extent (<1%) in the Old-World monkeys (Fig. 6B).  In none of the other 212 
species examined was there any utilization of an exon corresponding to human exon 0, with the 5' of 213 
exon 3 being spliced only to exon 1 or exon 2, except for the mouse lemur where a sequence between 214 
exons 1 and 2 was utilized to a minor extent (~3%). 215 
 216 
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The relative importance of exons 1 and 2 varies markedly between species, with exon 1 predominating 217 
in some species, including the apes and mouse lemur, but close to equal usage of exons 1 and 2 in some 218 
cases (e.g. galago and rat) (Fig. 6B). Notably, in the two New-World monkeys use of exon 2 219 
predominates (Fig. 6B); the IGF-I system is unusual in this group in several other ways, including 220 
accelerated evolution of IGF-I and of its receptor [29].  221 
 222 
3.4. IGF-I alternative splicing in human tumours 223 
As indicated, in normal human tissues, utilization of exon 0 is confined largely to liver. The possibility 224 
that this exon is expressed in tumours was explored by examining SRA transcriptomic databases for a 225 
number of human cancers.  In a number of tumour types examined, including breast, colorectal and 226 
uterine cancer and Ewing sarcoma (SRA projects SRP63460, SRP042620, SRP029880, SRP060016) 227 
utilization of exon 0 was not detected.  In endometrial cancer (SRP040442) very low expression of 228 
exon 1 was detected in 2 of the 9 individuals studied, a level similar to that seen in normal 229 
endometrium. Low expression of exon 1 was also detected infrequently in lung cancer (in 2 of 40 230 
individuals examined; project  ERP001058). 231 
 232 
The situation in prostate cancer is markedly different, as seen in three SRA projects (ERP000550, 233 
ERP017433, ERP006077). Study ERP006077 [30] included the largest number of cases, and results 234 
derived from this are shown in Fig. 7; similar results were obtained for the other two studies. 235 
Expression levels of IGF-I (Fig. 7A) in most tumours were similar to those in normal prostate (Fig. 4), 236 
but in some they were much lower and in one case (T23) markedly higher. Many of these tumours 237 
showed utilization of exon 0, with 17/25 showing such utilization at >1% of all 5' splices to exon 3, 238 
6/25 utilization at >10%, and in one case >25% (Fig. 7B).  Utilization of exon 0 in normal prostate is 239 
very low (<1% in the study of Fig. 4; no expression detected in two other studies, ERP076277, 240 
SRP163292). For 5 of the patients included in the project illustrated in Fig. 7 apparently normal tissue 241 
adjacent to the prostate tumour was also investigated; utilization of exon 0 was very low (<1%) in 3 of 242 
these cases, but it was higher (1.7% and 9.0%) in the other 2. 243 
 244 
Many liver tumours express IGF-I at levels similar to those seen in normal liver (SRA studies 245 
SRP030040, SRP064431, SRP007560). Utilization of exon 0 in these tumours was variable, but 246 
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generally rather lower than that seen in normal liver (Fig. 3) or, in most cases, apparently normal tissue 247 
adjacent to the tumours. Fig. 8 summarises data derived from study SRP064431. 248 
 249 
 250 
4. Discussion 251 
 252 
Alternative splicing of the IGF-I gene has been recognized for many years, with, in mammals, the 6 253 
exons of this complex gene differentially spliced at both the 5' and 3' ends, resulting in at least 6 254 
different mRNAs and IGF-I precursors, all including the mature IGF-I sequence [1-3,6]. At the 5' end 255 
of the gene, two exons have been identified, exons 1 and 2 (Fig. 1), either of which can be spliced to 256 
exon 3. The relative usage of these 5' exons in various tissues, developmental stages and disease 257 
conditions has been widely studied, but their significance remains unclear. Usage of exon 1 is generally 258 
greater than that of exon 2, although the ratio between the two varies and relative exon 2 usage is 259 
increased by growth hormone treatment [19]. For both these exons the transcription start points can 260 
vary, giving mRNAs with 5' utrs of differing length [14,15].  Initiation of translation can occur within 261 
both exon 1 and exon 2, giving signal peptides of 48 or 32 aas respectively, of which the C-terminal 27 262 
residues are encoded by exon 3 and therefore identical in the two signal peptides [13].  Initiation can 263 
also occur within exon 3, giving a signal peptide of 22 aas in rat (25 aas in human); exons 1 and 2 264 
would then be untranslated. Initiation within exons 2 or 3 is more efficient than within exon 1 [13], so 265 
the higher usage of exon 1 may not necessarily mean that it is of more importance in overall IGF-I 266 
production. The 48-residue signal peptide encoded when initiation occurs within exon 1 is 267 
exceptionally long, and may have a specific role, such as directing the protein to a particular 268 
subcellular compartment.   269 
 270 
It is shown here that in human the situation is further complicated by utilization of an additional 271 
upstream exon (exon 0) in the IGF-I gene. Alternative splicing of this gives rise to two novel leader 272 
sequences; in the predominant one exon 0 is spliced directly to exon 3, while less frequently exon 0 is 273 
spliced into exon 1. Utilization of exon 0 in human IGF-I has not been generally recognized previously 274 
and is not shown in the GTEx database (https://gtexportal.org/home/gene/IGF1), though it is predicted 275 
in three entries in the ncbi nucleotide database (www.ncbi.nlm.nih.gov/nuccore/), produced by 276 
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automated computer analysis (Variant X1, XM_017019259; Variant X3, XM_017019262; Variant X4, 277 
XM_017019263). In normal human tissues utilization of exon 0 is confined mostly to liver, where it 278 
comprises about 24% of splices to exon 3 (Fig. 3, Fig. 4).  An AUG/ATG codon 114 nt upstream of the 279 
splice site would be in-frame with the IGF-I mature sequence when exon 0 is spliced to exon 3, giving 280 
a very long putative signal peptide of 65 aas. Whether translation does in fact initiate at this site is not 281 
clear. Analysis of transcriptomic data cannot define precisely the transcription start point, but few 282 
transcripts extend up 114 nt from the splice site, and those that do mostly extend only a short distance 283 
upstream of this point (Fig. 5). There does not appear to be a TATA box or CCAAT element upstream 284 
of the exon 0 sequence, suggesting that as for exon 1 multiple transcription start points may apply, so 285 
many of the transcripts may be too short to allow translation initiation at the in-frame AUG/ATG. 286 
Translation would then probably start at the AUG 7 nt from the 5' end of exon 3-derived sequence, 287 
giving a signal peptide of 25 aas.  In the exon 0-exon 1-exon 3 variant, the AUG/ATG 114 nt upstream 288 
of the exon 0 splice site would not be in-frame, but an AUG/ATG 22 nt downstream of this would, 289 
potentially allowing translation of a precursor with a very long signal peptide of 85 aas. 290 
 291 
The origin of exon 0 has been clarified by analysing sequences from various primates. A sequence 292 
upstream of exon 1 similar to that of human exon 0 was identifiable in all primates, and in several non-293 
primate mammals, but not rat, where homologous sequence may be absent or just unrecognizable due 294 
to divergent evolution. Utilization of exon 0, judged by its appearance in liver transcripts, is only seen 295 
in Old World monkeys and apes, and in the former is very low (< 1% of all splices to exon 3; Fig. 6).  296 
It would thus appear that exon 0 arose by exaption of an existing sequence present upstream of the 297 
IGF-I gene, possibly only becoming fully functional in apes. Also notable from the comparative study 298 
of Fig. 6 are (1) the relatively low expression of IGF-I in human liver compared with many other 299 
species, the contrast being particularly marked in the case of rat, and (2) the rather low utilization of 300 
exon 2 in human and other apes, compared with most other primates and non-primate mammals. 301 
 302 
Expression of exon 0 was largely confined to liver and not detected in 29 other human tissues 303 
examined, though very low expression was detected in prostate and endometrium. Notably, for many of 304 
these  tissues, expression of IGF-I was similar to, or higher than, that in liver, though variation between 305 
individuals was high. Unlike exon 0, expression of exon 2 was seen in most human tissues,but always 306 
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less than that of exon 1, though the ratio between the two varied considerably. ANOVA showed that 307 
such variation was significant, indicating independent regulation of the expression of these two exons. 308 
 309 
The potential involvement of IGF-I in cancer has been discussed extensively [31-37], and the 310 
possibility of aberrant expression of exon 0 in cancer was investigated. In most cancers examined 311 
expression of exon 0 was absent (breast, colorectal, uterus, Ewing sarcoma) or very low (endometrium, 312 
lung). A marked exception was prostate cancer, where a high proportion of patients showed substantial 313 
expression of exon 0.  The significance of this is unclear, but the abnormal expression of a potent 314 
growth factor could well play a part in tumour growth and progression. Exon 0 expression was also 315 
seen in liver cancer (Fig. 8), but at a rather lower level than seen in normal liver tissue. 316 
 317 
In conclusion, the study described here shows that in human and apes, the IGF-I gene includes a novel 318 
exon, at the 5' end. Alternative splicing allows either exon 0, exon 1 or exon 2 to be spliced to exon 3, 319 
potentially giving 3 IGF-I precursors with different signal peptides. A further minor variant can also be 320 
produced, resulting from splicing of exon 0 into exon 1. Since alternative splicing also occurs at the 3' 321 
end of the IGF-I gene the total number of potential variants of the IGF-I precursor becomes quite large. 322 
The significance of the alternative leader sequences for human IGF-I remains unclear, but it is notable 323 
that unlike exons 1 or 2 utilization of exon 0 is very tissue specific, for normal tissues being confined 324 
largely to liver. In mice prevention of utilization of exon 2 has no apparent effect on development, 325 
growth or circulating IGF-I levels [38]. Whether the same might be true for exon 0 in humans is not 326 
clear, but its utilization in many prostate tumours does suggest that it may play a role in human disease. 327 
 328 
 329 
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 487 
Fig. 1. The human IGF-I gene. A. Organization of the gene showing the 6 previously-recognized exons 488 
(solid rectangles), the novel exon 0 (open rectangle), and the possible alternative splices at the 5' end, 489 
the minor exon 0-exon 1-exon 3 variant being shown with dotted lines.  Introns 3 and 5 are shown 490 
truncated; their full lengths are approx. 55.9 kb (intron 3) and 14.9 kb (intron 5). B. Sequence of exon 491 
0. The start of the exon at the 5' end is poorly defined and there may be multiple transcription start 492 
points; the region under the dashes is represented in few transcripts. Flanking sequences are shown in 493 
light grey. C. The potential signal peptide derived from exon 0 spliced to exon 3. Solid arrows indicate 494 
possible translation initiation sites; which of these is actually used is not clear (see text). The N-495 
terminal end of mature IGF-I is also included; the broken arrow indicates the cleavage site for the 496 
signal peptide. 497 
 498 
Fig. 2. Exon profile for the 5' end of IGF-I gene in human liver transcriptome (SRA project 499 
ERP003613; 5 experiments combined). Arrows indicate positions of in-frame translation initiation sites 500 
(ATG/AUG). 501 
 502 
Fig. 3. Utilization of exons 0, 1 and 2 in human liver. Values are means ± SEM for 11 individuals from 503 
5 SRA projects.  504 
 505 
Fig. 4. Expression level and 5' exon utilization for IGF-I in human tissues. Based on data in SRA 506 
projects ERP003613 and ERP006650. A. Expression level (BLAST hits/106 reads), based on BLAST 507 
searching with the sequence encoding mature human IGF-I. B. Utilization of exons 0, 1 and 2 in each 508 
tissue, expressed as a percentage of all splices to exon 3. The exon 0-exon 3 and exon 0-exon 1-exon 3 509 
splices were combined. Error bars show S.E.M. for 2-7 individuals. 510 
 511 
Fig. 5. Sequences of IGF-I exon 0 region for a number of primates and other mammals. The human 512 
sequence is given in full. For other sequences, a dot (.) indicates identity to human and a dash (-) 513 
indicates a gap. The exon 0 region is included in the large box, which is open at the left hand side 514 
because the 5' end is not defined. ATG-1 and ATG-2 indicate the positions of two potential translation 515 
start sites, in-frame in some sequences (see text). a and b indicate the 5' limits seen in the human 516 
  
19 
normal liver transcriptomes, b being reached in all 5 projects studied (including that illustrated in Fig. 517 
2), a in only two projects. Abbreviations of species names are as follows: Hsa, Homo sapiens (human), 518 
Ptr, Pan troglodytes (chimpanzee), Ggo, Gorilla gorilla (gorilla), Ppy, Pongo pygmaeus (orangutan), 519 
Nle, Nomascus leucogenys (gibbon), Mmu, Macaca mulatta (rhesus macaque), Csa, Chlorocebus 520 
sabaeus (African green monkey), Cja, Callithrix jacchus (marmoset), Sbo, Saimiri boliviensis (squirrel 521 
monkey), Tsy, Tarsius syrichta (tarsier), Mmur, Microcebus murinus (mouse lemur), Oga, Otolemur 522 
garnettii (galago), Tbe, Tupaia belangeri (tree shrew), Ocu, Oryctolagus cuniculus (rabbit), Cfa, Canis 523 
familiaris (dog). 524 
 525 
Fig. 6. Expression level and 5' exon utilization for IGF-I in liver of various primates plus tree shrew, 526 
rat, rabbit and dog. A. Expression level (BLAST hits/106 reads), based on BLAST searching with the 527 
sequence encoding mature IGF-I for the appropriate species. Numbers in brackets indicate the number 528 
of individuals in the sample. B. Utilization of exons 0 (white), 1 (grey) and 2 (black) in each tissue, 529 
expressed as a percentage of all splices to exon 3. The exon 0-exon 3 and exon 0-exon 1-exon 3 spliced 530 
forms were combined. Error bars show ± S.E.M. except where n<3, where individual values are shown 531 
(x). Species abbreviations as for Fig. 5 plus Rno, Rattus norvegicus (rat).  532 
 533 
Fig. 7. Expression level and 5' exon utilization for IGF-I in prostate cancers from 25 individual 534 
patients. Based on data in SRA project ERP006077. A. Expression level (BLAST hits/106 reads), based 535 
on BLAST searching with the sequence encoding mature IGF-I.  B. Utilization of exons 0 (light grey), 536 
1 (grey) and 2 (black) in each tumour, expressed as a percentage of all splices to exon 3. The exon 0-537 
exon 3 and exon 0-exon 1-exon 3 spliced forms were combined. Error bars show ± S.E.M. except 538 
where n<3. n = 3, except where individual points are shown (x, n = 1 or 2). 539 
 540 
Fig 8. Expression level and 5' exon utilization for IGF-I in liver cancers from 4 individual patients. 541 
Based on data in SRA project SRP064431. A. Expression level (BLAST hits/106 reads), based on 542 
BLAST searching with the sequence encoding mature human IGF-I for each tumour (T) or adjacent 543 
apparently normal tissue (N). B. Utilization of exons 0 (white), 1 (grey) and 2 (black) in each tumour 544 
(T) or adjacent apparently normal tissue (N), expressed as a percentage of all splices to exon 3. The 545 
exon 0-exon 3 and exon 0-exon 1-exon 3 spliced forms were combined. 546 
 547 
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